CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Novo Holdings-backed Windward Bio raises $175 million in US IPO

By Reuters News

Nov 12 (Reuters) - Novo Holdings-backed Windward Bio said on Thursday it had raised $175 million in its US initial public offering after selling about 10.3 million shares at $17 apiece.

The IPO price was within its marketed range of $16 to $18.

Basel, Switzerland-based Windward, which is developing antibody medicines for patients with serious respiratory and dermatologic diseases, will start trading on Friday under the symbol "WWB."

Here are more details:

  • Winward's lead candidate, WIN378, aims to treat asthma and chronic obstructive pulmonary disease by blocking a protein that contributes to airway inflammation

  • French ​drugmaker ⁠Sanofi SASY.PA has agreed to purchase $50 million of shares and pre-funded warrants in a private placement

  • Led by CEO and founder, Luca Santarelli, Windward has raised $310 million in equity financing from Novo Holdings and other healthcare investors, including OrbiMed, Blue Owl ​and RTW ​Investments

  • Santarelli's previous ventures include VectivBio, which was acquired by Ironwood Pharmaceuticals IRWD.O for $1.2 billion in 2023, while Pfizer PFE.N acquired Therachon in 2019 for $810 million

  • Healthcare and biotechnology companies have accounted for a flurry of US listings this fall, while macroeconomic headwinds have dampened IPO activity in other sectors

  • Jefferies, TD Cowen, Piper Sandler and UBS Investment Bank are underwriting the offering

  • Zug, Switzerland-based dental firm vVardis is also expected to go public on Friday

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.